読み込み中
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
前日終値
$10.16
+$1.22 · +13.65%
日中の時刻はETです。市場データは遅延する場合があります。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日中レンジ
現在 $10.16
52週レンジ
現在 $10.16
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
7
著しい割高
センチメント
64
強気
リスク
56
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
日中レンジ
現在 $10.16
52週レンジ
現在 $10.16
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 280万 USD | 453.4万 USD | 571.8万 USD | 574.7万 USD | 478.2万 USD |
| 売上原価 | 1174.2万 USD | 6245.9万 USD | 4756.7万 USD | 5890.8万 USD | 4458.6万 USD |
| 粗利益 | −894.2万 USD | −5792.5万 USD | −4184.9万 USD | −5316.1万 USD | −3980.4万 USD |
| 研究開発 | 8141.8万 USD | 6385.9万 USD | 4806.7万 USD | 5890.8万 USD | 4458.6万 USD |
| 販売・一般管理 | 3505.8万 USD | — | — | — | — |
| 営業費用 | 1.16億 USD | 5096.3万 USD | 7366.6万 USD | 5358.9万 USD | 3543.4万 USD |
| 支払利息 | 20.9万 USD | 56.5万 USD | 101万 USD | 97.2万 USD | 343.2万 USD |
| 減価償却費と償却費 | 1174.2万 USD | 1338.9万 USD | 1399.9万 USD | 1310万 USD | 665.4万 USD |
| 営業利益 | −1.25億 USD | −1.09億 USD | −1.16億 USD | −1.07億 USD | −7523.8万 USD |
| 純利益 | −1.15億 USD | −1.03億 USD | −1.11億 USD | −1.05億 USD | −1.01億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
ARK Genomic Revolution ETFARKG9459.5万4.62%15.57億 USD0.75%$51.30+4.08%
State Street SPDR S&P Biotech ETFXBI4481.88万0.45%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI4034.32万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3534.87万0.05%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1439.53万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1035.75万0.08%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB1024.01万0.10%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA765.87万0.04%218.24億 USD0.03%$32.79+0.40%ARK Genomic Revolution ETFARKGState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
